PRLD Prelude Therapeutics


Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
On June 18, 2021, Prelude Therapeutics Incorporated (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) and the following proposals were adopted:

1.Election of two Class I Directors, Paul A. Friedman, M.D., and David Bonita, M.D., each to serve a three-year term, which will expire at the 2024 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director’s earlier resignation or removal. The vote tally was as follows:

NomineesShares ForShares WithheldBroker Non-Votes
Paul A. Friedman, M.D.28,275,6561,344,710447,075
David Bonita, M.D.27,793,8591,826,507447,075

2.Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021. The vote tally was as follows:

Shares ForShares AgainstShares Abstaining